Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shi-Ming Tu

Showing results (121-130 of 131) with videos related to

Pageof 14
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2009
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancerMary-Ellen Taplin, Meredith M Regan, Yoo-Joung Ko, et al.
Oncotarget|November 19, 2016
Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testisMehmet Asim Bilen, Kenneth R Hess, Matthew T Campbell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastasesPaul Mathew, Peter F Thall, Corazon D Bucana, et al.
Clinical Genitourinary Cancer|July 18, 2020
A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate CancerNicholas Spetsieris, Myrto Boukovala, Justin A Weldon, et al.
NPJ Precision Oncology|March 20, 2021
Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) studyApostolia Maria Tsimberidou, David S Hong, Siqing Fu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2020
A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate CancerPaul G Corn, Miao Zhang, Graciela M Nogueras-Gonzalez, et al.
Cancer|March 29, 2016
Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancerShi-Ming Tu, Mehmet Asim Bilen, Kenneth R Hess, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2025
HIGH-DOSE CHEMOTHERAPY FOR MULTIPLY OR POOR-RISK RELAPSED GERM-CELL TUMORSYago Nieto, John F Ward, Wayne Hofstetter, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 4, 2011
Vascular ligand-receptor mapping by direct combinatorial selection in cancer patientsFernanda I Staquicini, Marina Cardó-Vila, Mikhail G Kolonin, et al.
Journal for Immunotherapy of Cancer|March 20, 2020
Phase 2 study of pembrolizumab in patients with advanced rare cancersAung Naing, Funda Meric-Bernstam, Bettzy Stephen, et al.
Pageof 14

Showing results (121-130 of 131) with videos related to

Sort By:
Pageof 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2009
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancerMary-Ellen Taplin, Meredith M Regan, Yoo-Joung Ko, et al.
Oncotarget|November 19, 2016
Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testisMehmet Asim Bilen, Kenneth R Hess, Matthew T Campbell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastasesPaul Mathew, Peter F Thall, Corazon D Bucana, et al.
Clinical Genitourinary Cancer|July 18, 2020
A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate CancerNicholas Spetsieris, Myrto Boukovala, Justin A Weldon, et al.
NPJ Precision Oncology|March 20, 2021
Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) studyApostolia Maria Tsimberidou, David S Hong, Siqing Fu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2020
A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate CancerPaul G Corn, Miao Zhang, Graciela M Nogueras-Gonzalez, et al.
Cancer|March 29, 2016
Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancerShi-Ming Tu, Mehmet Asim Bilen, Kenneth R Hess, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2025
HIGH-DOSE CHEMOTHERAPY FOR MULTIPLY OR POOR-RISK RELAPSED GERM-CELL TUMORSYago Nieto, John F Ward, Wayne Hofstetter, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 4, 2011
Vascular ligand-receptor mapping by direct combinatorial selection in cancer patientsFernanda I Staquicini, Marina Cardó-Vila, Mikhail G Kolonin, et al.
Journal for Immunotherapy of Cancer|March 20, 2020
Phase 2 study of pembrolizumab in patients with advanced rare cancersAung Naing, Funda Meric-Bernstam, Bettzy Stephen, et al.
Pageof 14